Published in Pharmacogenetics on August 01, 2002
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Pharmacogenetics of beta-blockers. Pharmacotherapy (2007) 1.13
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther (2014) 1.05
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol (2006) 1.03
CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol (2008) 0.91
Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol (2003) 0.89
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol (2007) 0.89
Genetic variation, β-blockers, and perioperative myocardial infarction. Anesthesiology (2011) 0.87
The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci (2006) 0.82
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol (2005) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Pharmacogenetic profiling in the treatment of heart disease. Transl Res (2009) 0.79
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev (2004) 0.79
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Population pharmacokinetics of bisoprolol in patients with chronic heart failure. Eur J Clin Pharmacol (2012) 0.78
The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol (2015) 0.77
Pharmacogenetics of ophthalmic topical beta-blockers. Per Med (2008) 0.77
Challenges in pharmacogenetics. Eur J Clin Pharmacol (2013) 0.76
Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Prefer Adherence (2016) 0.75
Genetic polymorphisms associated with heart failure: A literature review. J Int Med Res (2016) 0.75
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. Pharm Res (2017) 0.75
Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med (2006) 4.74
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation (2006) 2.26
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res (2005) 2.08
Development of a drug screening platform based on engineered heart tissue. Circ Res (2010) 2.04
Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation (2006) 2.00
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol (2007) 1.85
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther (2002) 1.84
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol (2010) 1.74
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One (2011) 1.73
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol (2004) 1.72
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol (2013) 1.68
Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66
Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation (2002) 1.65
Regulation of cardiac cAMP synthesis and contractility by nucleoside diphosphate kinase B/G protein beta gamma dimer complexes. Circ Res (2007) 1.58
Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression: involvement of protein kinase A and calmodulin-dependent kinase. Cardiovasc Res (2003) 1.56
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation (2009) 1.54
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. Hepatology (2003) 1.52
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res (2007) 1.50
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med (2010) 1.49
Engineering bioartificial tracheal tissue using hybrid fibroblast-mesenchymal stem cell cultures in collagen hydrogels. Interact Cardiovasc Thorac Surg (2010) 1.46
Cardiac grafting of engineered heart tissue in syngenic rats. Circulation (2002) 1.43
Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res (2008) 1.42
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res (2004) 1.38
Engineered heart tissue for regeneration of diseased hearts. Biomaterials (2004) 1.36
Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res (2006) 1.32
Cardiac tissue engineering: state of the art. Circ Res (2014) 1.30
Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest (2010) 1.29
Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. Biomed Chromatogr (2003) 1.29
Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res (2009) 1.26
Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics (2002) 1.23
Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. Cardiovasc Res (2002) 1.21
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20
Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res (2009) 1.18
Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun (2006) 1.17
Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure. Biochem Biophys Res Commun (2002) 1.17
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet (2012) 1.16
Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol (2012) 1.13
Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J (2003) 1.13
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord (2005) 1.12
Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/ AKT pathway. Circ Res (2007) 1.12
Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res (2011) 1.12
Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest (2013) 1.11
Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol (2013) 1.11
Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. Basic Res Cardiol (2011) 1.10
Cardiac tissue engineering for replacement therapy. Heart Fail Rev (2003) 1.09
High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther (2006) 1.08
Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen. J Clin Pharmacol (2007) 1.07
Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation (2002) 1.07
Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart. Circ Res (2012) 1.06
Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol (2012) 1.06
Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J (2006) 1.04
Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue. J Mol Cell Cardiol (2007) 1.03
Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med (2013) 1.01
Phosphatase-1 inhibitor-1 in physiological and pathological β-adrenoceptor signalling. Cardiovasc Res (2011) 1.01
Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol (2013) 1.00
Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res (2003) 0.99
The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J (2014) 0.97
The slow force response to stretch in atrial and ventricular myocardium from human heart: functional relevance and subcellular mechanisms. Prog Biophys Mol Biol (2008) 0.97
Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol (2006) 0.96
Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix. PLoS One (2012) 0.95
Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet (2013) 0.95
Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res (2005) 0.95
Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice. J Muscle Res Cell Motil (2011) 0.95
Beta-adrenergic signaling in heart failure-adapt or die. Nat Med (2008) 0.94
Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance. J Mol Cell Cardiol (2008) 0.93
Long-term beta-adrenergic stimulation leads to downregulation of protein phosphatase inhibitor-1 in the heart. Eur J Heart Fail (2007) 0.93
Myomasp/LRRC39, a heart- and muscle-specific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing. Circ Res (2010) 0.93
Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ Heart Fail (2011) 0.93
The MLCK-mediated alpha1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCepsilon signaling. Br J Pharmacol (2006) 0.93
Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J (2008) 0.93
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res (2003) 0.93
Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol (2014) 0.92
Hemodynamic efficacy of sequential hemoclip application using the Olympus HX-110/610 reloadable clipping device in spurting bleedings. Med Sci Monit (2011) 0.92
Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy. Mol Ther Nucleic Acids (2013) 0.92
S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med (2004) 0.91
Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochem Biophys Res Commun (2008) 0.90
ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.90
Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes. FASEB J (2003) 0.89
Melusin protects from cardiac rupture and improves functional remodelling after myocardial infarction. Cardiovasc Res (2013) 0.89
Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization. Antioxid Redox Signal (2013) 0.88
Embryonic stem cells for cardiac muscle engineering. Trends Cardiovasc Med (2007) 0.88
The effect of mesenchymal stem cell osteoblastic differentiation on the mechanical properties of engineered bone-like tissue. Tissue Eng Part A (2011) 0.87
In vitro perfusion of engineered heart tissue through endothelialized channels. Tissue Eng Part A (2013) 0.87
Development of a biological ventricular assist device: preliminary data from a small animal model. Circulation (2007) 0.87
Distinction between two populations of islet-1-positive cells in hearts of different murine strains. Stem Cells Dev (2010) 0.87
Reproducibility of transthoracic echocardiography in small animals using clinical equipment. Coron Artery Dis (2007) 0.87
Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation. J Biol Chem (2013) 0.86
Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol (2012) 0.86
Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc Res (2009) 0.86
Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium. Cardiovasc Res (2008) 0.86
A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity. Eur J Heart Fail (2012) 0.86